Loading...
XNASCLPT
Market cap416mUSD
Jan 15, Last price  
15.12USD
1D
2.86%
1Q
25.33%
Jan 2017
344.56%
IPO
287.56%
Name

Clearpoint Neuro Inc

Chart & Performance

D1W1MN
XNAS:CLPT chart
P/E
P/S
17.41
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
17.62%
Rev. gr., 5y
26.64%
Revenues
24m
+16.56%
2,669,4503,818,1665,058,2353,930,5753,604,4824,594,1925,749,4547,379,5257,353,26611,216,93712,829,00016,299,00020,551,00023,955,000
Net income
-22m
L+33.57%
-9,454,235-8,311,411-5,707,136-7,086,274-4,524,732-8,449,246-8,069,895-7,167,353-6,163,469-6,504,010-9,108,000-15,320,000-16,538,000-22,089,000
CFO
-14m
L-15.14%
-7,707,253-6,239,595-7,433,816-7,777,931-7,250,303-8,637,734-5,820,043-5,992,511-4,630,592-2,849,514-7,808,000-12,697,000-16,167,000-13,720,000
Earnings
May 05, 2025

Profile

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
IPO date
Jul 03, 2019
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
23,955
16.56%
20,551
26.09%
Cost of revenue
46,401
36,883
Unusual Expense (Income)
NOPBT
(22,446)
(16,332)
NOPBT Margin
Operating Taxes
103
Tax Rate
NOPAT
(22,446)
(16,435)
Net income
(22,089)
33.57%
(16,538)
7.95%
Dividends
Dividend yield
Proceeds from repurchase of equity
296
409
BB yield
-0.18%
-0.20%
Debt
Debt current
848
561
Long-term debt
17,509
13,518
Deferred revenue
541
390
Other long-term liabilities
(9,893)
Net debt
(4,783)
(23,410)
Cash flow
Cash from operating activities
(13,720)
(16,167)
CAPEX
(717)
(1,146)
Cash from investing activities
8,949
(10,736)
Cash from financing activities
296
409
FCF
(23,684)
(20,283)
Balance
Cash
23,140
37,489
Long term investments
Excess cash
21,942
36,461
Stockholders' equity
(172,209)
(150,121)
Invested Capital
208,288
189,491
ROIC
ROCE
EV
Common stock shares outstanding
24,605
24,182
Price
6.79
-19.83%
8.47
-24.51%
Market cap
167,069
-18.43%
204,820
-11.96%
EV
162,286
181,410
EBITDA
(20,989)
(15,555)
EV/EBITDA
Interest
81
Interest/NOPBT